Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2020-02-26 21:42:01 UTC
HMDB IDHMDB0015666
Secondary Accession Numbers
  • HMDB15666
Metabolite Identification
Common NameLornoxicam
DescriptionLornoxicam, also known as XEFO or acabel, belongs to the class of organic compounds known as thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Thiazine is a 6-membered ring consisting of four carbon, one nitrogen and one sulfur atoms. Lornoxicam is a strong basic compound (based on its pKa). In humans, lornoxicam is involved in lornoxicam action pathway. Lornoxicam is approved for use in Japan. Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.
Structure
Data?1582753321
Synonyms
ValueSource
AcabelHMDB
ChlortenoxicamHMDB
CLTXHMDB
LorcamHMDB
LornoxicamumHMDB
SafemHMDB
TaigalorHMDB
TelosHMDB
XEFOHMDB
XefocamHMDB
Chemical FormulaC13H10ClN3O4S2
Average Molecular Weight371.819
Monoisotopic Molecular Weight370.98012491
IUPAC Name(3E)-6-chloro-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-2H,3H,4H-1λ⁶-thieno[2,3-e][1,2]thiazine-1,1,4-trione
Traditional Nametelos
CAS Registry Number70374-39-9
SMILES
CN1\C(=C(\O)NC2=CC=CC=N2)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O
InChI Identifier
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,19H,1H3,(H,15,16)/b13-10+
InChI KeyOXROWJKCGCOJDO-JLHYYAGUSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Thiazine is a 6-membered ring consisting of four carbon, one nitrogen and one sulfur atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThienothiazines
Sub ClassNot Available
Direct ParentThienothiazines
Alternative Parents
Substituents
  • Thienothiazine
  • 2,3,5-trisubstituted thiophene
  • Aryl ketone
  • Secondary aliphatic/aromatic amine
  • Ortho-thiazine
  • Aryl chloride
  • Aryl halide
  • Pyridine
  • Organosulfonic acid amide
  • Imidolactam
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Heteroaromatic compound
  • Thiophene
  • Vinylogous amide
  • Vinylogous acid
  • Ketone
  • Secondary amine
  • Alkanolamine
  • Azacycle
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Organic oxygen compound
  • Organopnictogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogP2.62BIOBYTE STARLIST (2009)
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.046 g/LALOGPS
logP2.53ALOGPS
logP1.99ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)6.88ChemAxon
pKa (Strongest Basic)4.78ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 ŲChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.02 m³·mol⁻¹ChemAxon
Polarizability33.77 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+174.03930932474
DeepCCS[M-H]-171.68130932474
DeepCCS[M-2H]-205.28430932474
DeepCCS[M+Na]+180.51230932474
AllCCS[M+H]+178.732859911
AllCCS[M+H-H2O]+175.832859911
AllCCS[M+NH4]+181.532859911
AllCCS[M+Na]+182.232859911
AllCCS[M-H]-174.732859911
AllCCS[M+Na-2H]-174.432859911
AllCCS[M+HCOO]-174.332859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
LornoxicamCN1\C(=C(\O)NC2=CC=CC=N2)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O4819.7Standard polar33892256
LornoxicamCN1\C(=C(\O)NC2=CC=CC=N2)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3083.9Standard non polar33892256
LornoxicamCN1\C(=C(\O)NC2=CC=CC=N2)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3193.3Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Lornoxicam,1TMS,isomer #1CN1/C(=C(\NC2=CC=CC=N2)O[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3067.3Semi standard non polar33892256
Lornoxicam,1TMS,isomer #2CN1/C(=C(/O)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3021.8Semi standard non polar33892256
Lornoxicam,2TMS,isomer #1CN1/C(=C(/O[Si](C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O2970.5Semi standard non polar33892256
Lornoxicam,2TMS,isomer #1CN1/C(=C(/O[Si](C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3196.7Standard non polar33892256
Lornoxicam,2TMS,isomer #1CN1/C(=C(/O[Si](C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O4057.1Standard polar33892256
Lornoxicam,1TBDMS,isomer #1CN1/C(=C(\NC2=CC=CC=N2)O[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3271.7Semi standard non polar33892256
Lornoxicam,1TBDMS,isomer #2CN1/C(=C(/O)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3248.8Semi standard non polar33892256
Lornoxicam,2TBDMS,isomer #1CN1/C(=C(/O[Si](C)(C)C(C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3310.4Semi standard non polar33892256
Lornoxicam,2TBDMS,isomer #1CN1/C(=C(/O[Si](C)(C)C(C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O3673.8Standard non polar33892256
Lornoxicam,2TBDMS,isomer #1CN1/C(=C(/O[Si](C)(C)C(C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O4063.3Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Lornoxicam GC-MS (Non-derivatized) - 70eV, Positivesplash10-0006-5921000000-6f9ae5cf4b1b0097a4062017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lornoxicam GC-MS (1 TMS) - 70eV, Positivesplash10-006y-7491100000-cfd19c2004e4ef1f72fd2017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lornoxicam GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lornoxicam GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 10V, Positive-QTOFsplash10-00dj-6039000000-5acd8e014a66cfeba2742017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 20V, Positive-QTOFsplash10-0002-9200000000-79cac3b848eaf37323a42017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 40V, Positive-QTOFsplash10-0002-9800000000-666e04068ab04bb095332017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 10V, Negative-QTOFsplash10-014i-3049000000-fd314afee7bb217013f72017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 20V, Negative-QTOFsplash10-0006-8900000000-559e35dd6fe4470b2b782017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 40V, Negative-QTOFsplash10-0089-3900000000-1e73e6eb2363580b2ef22017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 10V, Positive-QTOFsplash10-00di-1009000000-ace9fdbf0f3a5ca12dc92021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 20V, Positive-QTOFsplash10-00dj-8439000000-3d1eb3b1155415f020022021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 40V, Positive-QTOFsplash10-004i-9100000000-81f13509aa816da18f322021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 10V, Negative-QTOFsplash10-014i-0019000000-5ccae5802952cfdead8b2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 20V, Negative-QTOFsplash10-0002-1192000000-9f2aef1c184c6a8f77e02021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lornoxicam 40V, Negative-QTOFsplash10-0006-9122000000-790da4b14580b297d68a2021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue Locations
  • Kidney
  • Liver
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB06725 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB06725 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID4445392
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkLornoxicam
METLIN IDNot Available
PubChem Compound5282204
PDB IDNot Available
ChEBI ID724428
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
  2. Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H: Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66 Suppl 4:S18-21. [PubMed:2284216 ]
  3. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D: Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66 Suppl 4:S22-7. [PubMed:2284217 ]
  4. Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. [PubMed:8162655 ]
  5. Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3. [PubMed:8630629 ]
  6. Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57. [PubMed:8706598 ]
  7. Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8. [PubMed:9646006 ]
  8. Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. [PubMed:12879104 ]

Enzymes

General function:
Involved in peroxidase activity
Specific function:
Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular weight:
68995.625
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943 ]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786 ]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707 ]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620 ]
General function:
Involved in peroxidase activity
Specific function:
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells.
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular weight:
68685.82
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943 ]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786 ]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707 ]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620 ]
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular weight:
55627.365
References
  1. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328 ]
  2. Martinez C, Blanco G, Garcia-Martin E, Agundez JA: [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs]. Farm Hosp. 2006 Jul-Aug;30(4):240-8. [PubMed:17022718 ]
  3. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H: Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005 Jan;59(1):14-7. [PubMed:15606435 ]
  4. Kohl C, Steinkellner M: Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8. [PubMed:10640513 ]
  5. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
  6. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  7. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]